{"address1": "700 Saginaw Drive", "city": "Redwood City", "state": "CA", "zip": "94063", "country": "United States", "phone": "650 481 6801", "website": "https://www.revmed.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline includes RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.", "fullTimeEmployees": 534, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mark A. Goldsmith Ph.D.", "age": 62, "title": "CEO, President & Chairman", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1115221, "exercisedValue": 2853049, "unexercisedValue": 32777390}, {"maxAge": 1, "name": "Mr. Jack  Anders", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 665284, "exercisedValue": 1024663, "unexercisedValue": 1206837}, {"maxAge": 1, "name": "Ms. Margaret A. Horn J.D.", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 811075, "exercisedValue": 1681564, "unexercisedValue": 10104314}, {"maxAge": 1, "name": "Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.", "age": 63, "title": "President of Research & Development", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 812175, "exercisedValue": 0, "unexercisedValue": 7521715}, {"maxAge": 1, "name": "Ms. Xiaolin  Wang", "age": 53, "title": "Executive Vice President of Development", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 633737, "exercisedValue": 0, "unexercisedValue": 7283126}, {"maxAge": 1, "name": "Dr. Martin D. Burke M.D., Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Fischbach Ph.D.", "age": 43, "title": "Academic Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevan M. Shokat Ph.D.", "title": "Academic Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Walter  Reiher Ph.D.", "title": "Chief Information Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jan  Smith Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 35.36, "open": 35.35, "dayLow": 33.25, "dayHigh": 36.05, "regularMarketPreviousClose": 35.36, "regularMarketOpen": 35.35, "regularMarketDayLow": 33.25, "regularMarketDayHigh": 36.05, "payoutRatio": 0.0, "beta": 1.457, "forwardPE": -8.301234, "volume": 2705697, "regularMarketVolume": 2705697, "averageVolume": 1354605, "averageVolume10days": 1422790, "averageDailyVolume10Day": 1422790, "bid": 25.46, "ask": 42.63, "bidSize": 1, "askSize": 1, "marketCap": 6250394624, "fiftyTwoWeekLow": 29.55, "fiftyTwoWeekHigh": 62.4, "fiftyDayAverage": 40.0812, "twoHundredDayAverage": 44.5387, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 4096950016, "profitMargins": 0.0, "floatShares": 168212518, "sharesOutstanding": 185912992, "sharesShort": 16652995, "sharesShortPriorMonth": 14924861, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0896, "heldPercentInsiders": 0.02049, "heldPercentInstitutions": 1.0632701, "shortRatio": 11.88, "shortPercentOfFloat": 0.094799995, "impliedSharesOutstanding": 185912992, "bookValue": 12.185, "priceToBook": 2.75913, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -600092992, "trailingEps": -3.58, "forwardEps": -4.05, "enterpriseToEbitda": -5.998, "52WeekChange": 0.0710417, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 33.62, "targetHighPrice": 87.0, "targetLowPrice": 59.0, "targetMeanPrice": 72.33333, "targetMedianPrice": 71.5, "recommendationMean": 1.30769, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 2289298944, "totalCashPerShare": 12.314, "ebitda": -682995968, "totalDebt": 135843008, "quickRatio": 13.966, "currentRatio": 14.2, "debtToEquity": 5.997, "returnOnAssets": -0.18656, "returnOnEquity": -0.29334, "grossProfits": -592225024, "freeCashflow": -347686496, "operatingCashflow": -557436032, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "RVMD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -4.920819, "regularMarketPrice": 33.62, "marketState": "PRE", "shortName": "Revolution Medicines, Inc.", "longName": "Revolution Medicines, Inc.", "fiftyDayAverageChange": -6.4612007, "fiftyDayAverageChangePercent": -0.16120277, "twoHundredDayAverageChange": -10.918701, "twoHundredDayAverageChangePercent": -0.24515088, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1581604200000, "preMarketChange": 0.31000137, "preMarketChangePercent": 0.9220743, "preMarketPrice": 33.93, "regularMarketChange": -1.7400017, "regularMarketDayRange": "33.25 - 36.05", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1354605, "fiftyTwoWeekLowChange": 4.0699997, "fiftyTwoWeekLowChangePercent": 0.13773265, "fiftyTwoWeekRange": "29.55 - 62.4", "fiftyTwoWeekHighChange": -28.780003, "fiftyTwoWeekHighChangePercent": -0.46121797, "fiftyTwoWeekChangePercent": 7.1041703, "earningsTimestamp": 1740603720, "earningsTimestampStart": 1746529140, "earningsTimestampEnd": 1747051200, "earningsCallTimestampStart": 1740605400, "earningsCallTimestampEnd": 1740605400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.58, "epsForward": -4.05, "epsCurrentYear": -4.47601, "priceEpsCurrentYear": -7.5111537, "corporateActions": [], "preMarketTime": 1743591256, "regularMarketTime": 1743537601, "exchange": "NMS", "messageBoardId": "finmb_283775412", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Revolution Medicines", "trailingPegRatio": null}